Semax

Research · Semax

Overview

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on a fragment of adrenocorticotropic hormone (ACTH 4-10) with a C-terminal Pro-Gly-Pro tripeptide extension that enhances stability and potency. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been approved as a pharmaceutical in Russia and Ukraine since the 1990s for nootropic and neuroprotective indications.

Mechanism of Action

Semax modulates multiple neurotrophic factors including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and tropomyosin receptor kinase B (TrkB) signaling. It influences the expression of over 24 genes related to neurotrophic support, immune modulation, and vascular function. Unlike ACTH, semax has no steroidogenic activity and does not affect cortisol levels.

Key Research Findings

1. 01

   Clinical studies in Russia showed semax improved cognitive function, attention, and memory in patients with cerebrovascular disease.

2. 02

   Preclinical models demonstrate semax increases BDNF expression in the hippocampus and cerebral cortex.

3. 03

   In ischemic stroke models, semax reduced infarct volume and improved neurological outcomes when administered within the acute treatment window.

4. 04

   Semax has been shown to modulate immune function, with effects on immunoglobulin levels and cytokine expression.

Published References

• Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus

  Dolotov OV et al. — Brain Res, 2006 · PMID: 16325779

The information above is derived from published preclinical and clinical research. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.